Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Device Impact on the Efficacy of Serum Product Study

10 novembre 2026 aggiornato da: ChinaNorm

The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:

- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?

Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.

Participants will:

  • Receive randomized split-face and split-neck treatment during the study
  • Attend 10 scheduled study visits
  • Undergo standardized image capture, clinical assessment and instrumental skin measurement

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

35

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina
        • Reclutamento
        • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 25 anni a 55 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • 1. Chinese female with 25 - 55 years old.
  • 2. All skin types, 50% self-declare sensitive skin.
  • 3. Self- declare with concerns on facial wrinkle problems.
  • 4. The difference in clinical grading between the two sides of the face should be less than one point.
  • 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
  • 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
  • 7. Did not participate any chemical/beauty procedures for previous 6 months.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
  • 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 10. Must be willing to comply with all study protocol requirements.

Exclusion Criteria:

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order.
  • 3. Major subject to a guardianship order.
  • 4. Subject residing in a health or social care establishment.
  • 5. Patient in an emergency setting.
  • 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
  • 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject.
  • 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject regularly practicing aquatic or nautical sports.
  • 12. Subject regularly attending a sauna.
  • 13. Subject with physical highly sensitive constitution.
  • 14. Subject with cardiovascular or circulatory history.
  • 15. Subject with a history of skin cancer or malignant melanoma.
  • 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1

Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen.

Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product.

Comparatore attivo: Arm 2

Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed.

Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Lasso di tempo: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline.

2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Stratum corneum hydration measured by Corneometer® CM 825
Lasso di tempo: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
Transepidermal water loss (TEWL) measured by Vapometer
Lasso di tempo: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
wrinkle analysis using Antera 3D
Lasso di tempo: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Skin texture analysis using VisioScan VC20
Lasso di tempo: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
3D facial imaging using Vectera-H2
Lasso di tempo: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Facial imaging acquisition using VISIA®-CR (Canfield)
Lasso di tempo: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 settembre 2026

Completamento primario (Effettivo)

10 novembre 2026

Completamento dello studio (Stimato)

30 novembre 2026

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • C26005101

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .